BRPI1014222A2 - composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar - Google Patents
composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolarInfo
- Publication number
- BRPI1014222A2 BRPI1014222A2 BRPI1014222A BRPI1014222A BRPI1014222A2 BR PI1014222 A2 BRPI1014222 A2 BR PI1014222A2 BR PI1014222 A BRPI1014222 A BR PI1014222A BR PI1014222 A BRPI1014222 A BR PI1014222A BR PI1014222 A2 BRPI1014222 A2 BR PI1014222A2
- Authority
- BR
- Brazil
- Prior art keywords
- cognitive impairment
- alzheimer
- indications
- disease
- compound
- Prior art date
Links
- 208000028698 Cognitive impairment Diseases 0.000 title 2
- 208000010877 cognitive disease Diseases 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 208000020925 Bipolar disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22165709P | 2009-06-30 | 2009-06-30 | |
| PCT/SE2010/050747 WO2011002405A1 (en) | 2009-06-30 | 2010-06-29 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014222A2 true BRPI1014222A2 (pt) | 2017-05-16 |
Family
ID=43381415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014222A BRPI1014222A2 (pt) | 2009-06-30 | 2010-06-29 | composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8367676B2 (pt) |
| EP (1) | EP2448934B1 (pt) |
| JP (1) | JP5767211B2 (pt) |
| KR (1) | KR20120110000A (pt) |
| CN (1) | CN102482264B (pt) |
| AR (1) | AR077301A1 (pt) |
| AU (1) | AU2010266753B2 (pt) |
| BR (1) | BRPI1014222A2 (pt) |
| CA (1) | CA2765475A1 (pt) |
| MX (1) | MX2011013449A (pt) |
| RU (1) | RU2011152516A (pt) |
| TW (1) | TW201103922A (pt) |
| UY (1) | UY32744A (pt) |
| WO (1) | WO2011002405A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| CA2821480A1 (en) | 2010-12-20 | 2012-06-28 | Astrazeneca Ab | 2-carboxamide-4-piperazinyl-benzofuran derivative |
| CN102993186B (zh) * | 2012-12-20 | 2015-11-18 | 北京海步国际医药科技发展有限公司 | 一种新型的哌嗪衍生物 |
| CN105339371A (zh) * | 2013-03-07 | 2016-02-17 | 葛兰素史密斯克莱有限责任公司 | 作为沉默调节蛋白调节剂的噻吩并[3,2-d]嘧啶-6-甲酰胺和类似物 |
| WO2020160151A1 (en) * | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| WO2021243421A1 (en) * | 2020-06-05 | 2021-12-09 | Monash University | Dual kinase-bromodomain inhibitors |
| CN117430574B (zh) * | 2023-12-20 | 2024-03-22 | 潍坊医学院 | 一种苯并呋喃衍生物及其制备方法、用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125900D0 (en) * | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| EP1007523B9 (en) | 1997-07-25 | 2004-09-08 | H. Lundbeck A/S | Indole and 2,3-dihydroindole derivatives, their preparation and use |
| AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| CA2450245A1 (en) | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| MXPA04012439A (es) | 2002-06-10 | 2005-04-19 | Bayer Healthcare Ag | Amidas de acidos 2-heteroarilcarboxilicos. |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| DE10259244A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
| DE10326939A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| DE10326940A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| WO2005077885A1 (en) | 2004-02-06 | 2005-08-25 | Yale University | Ruthenium-catalyzed hydroamination of olefins |
| WO2006062481A1 (en) | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
| WO2007053093A1 (en) | 2005-11-04 | 2007-05-10 | Astrazeneca Ab | Chroman compounds as 5 ht1b antagonists |
| AR059356A1 (es) | 2006-02-14 | 2008-03-26 | Astrazeneca Ab | Nuevos radioligandos |
| JP2010504367A (ja) | 2006-09-26 | 2010-02-12 | グラクソ グループ リミテッド | 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体 |
| BRPI0718776A2 (pt) | 2006-11-09 | 2013-12-03 | Hoffmann La Roche | Derivados de indol e benzofurano 2-carboxamida |
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
-
2010
- 2010-06-28 US US12/824,567 patent/US8367676B2/en active Active
- 2010-06-29 KR KR1020117031427A patent/KR20120110000A/ko not_active Application Discontinuation
- 2010-06-29 MX MX2011013449A patent/MX2011013449A/es active IP Right Grant
- 2010-06-29 JP JP2012518512A patent/JP5767211B2/ja not_active Expired - Fee Related
- 2010-06-29 TW TW099121305A patent/TW201103922A/zh unknown
- 2010-06-29 CN CN201080038560.6A patent/CN102482264B/zh not_active Expired - Fee Related
- 2010-06-29 BR BRPI1014222A patent/BRPI1014222A2/pt not_active IP Right Cessation
- 2010-06-29 EP EP10794458.9A patent/EP2448934B1/en active Active
- 2010-06-29 AU AU2010266753A patent/AU2010266753B2/en not_active Ceased
- 2010-06-29 RU RU2011152516/04A patent/RU2011152516A/ru not_active Application Discontinuation
- 2010-06-29 UY UY0001032744A patent/UY32744A/es unknown
- 2010-06-29 WO PCT/SE2010/050747 patent/WO2011002405A1/en active Application Filing
- 2010-06-29 CA CA2765475A patent/CA2765475A1/en not_active Abandoned
- 2010-06-30 AR ARP100102339A patent/AR077301A1/es unknown
-
2013
- 2013-02-04 US US13/758,098 patent/US8859534B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130296296A1 (en) | 2013-11-07 |
| EP2448934B1 (en) | 2014-05-21 |
| WO2011002405A1 (en) | 2011-01-06 |
| TW201103922A (en) | 2011-02-01 |
| US8859534B2 (en) | 2014-10-14 |
| CN102482264B (zh) | 2015-10-07 |
| CN102482264A (zh) | 2012-05-30 |
| MX2011013449A (es) | 2012-02-13 |
| AU2010266753B2 (en) | 2013-08-08 |
| US20100331341A1 (en) | 2010-12-30 |
| EP2448934A1 (en) | 2012-05-09 |
| RU2011152516A (ru) | 2013-08-10 |
| US8367676B2 (en) | 2013-02-05 |
| UY32744A (es) | 2011-01-31 |
| CA2765475A1 (en) | 2011-01-06 |
| AR077301A1 (es) | 2011-08-17 |
| KR20120110000A (ko) | 2012-10-09 |
| JP2012532125A (ja) | 2012-12-13 |
| JP5767211B2 (ja) | 2015-08-19 |
| AU2010266753A1 (en) | 2012-01-19 |
| EP2448934A4 (en) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014222A2 (pt) | composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar | |
| BRPI0914902A2 (pt) | composição farmacêutica e método para tratamento de mal de parkinson | |
| BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
| BRPI1013559A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos | |
| BRPI1009252A2 (pt) | composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo | |
| BRPI0816175A2 (pt) | Composições adequadas para tratamento de doença, distúrbio ou condição da espinha. | |
| BR112012002124A2 (pt) | tratamento da doença de crohn com laquinimode. | |
| BRPI1012993A2 (pt) | "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro" | |
| BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BR112012003464A2 (pt) | composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio." | |
| BRPI1004899A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac | |
| BRPI0813212A2 (pt) | Métodos de tratamento de doenças e distúrbios mediados por serotonina | |
| BRPI1009920A2 (pt) | composições bacterianas para profilaxina e tratamento de doença degenerativa. | |
| BRPI0917567A2 (pt) | tratamento de doença respiratória | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BRPI0809890A2 (pt) | Processo para preparar imatinib ou sal do mesmo e composição farmacêutica | |
| BRPI0822572A2 (pt) | Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
| BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| BRPI1006145A2 (pt) | "composição e método para tratamento de diabetes". |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |